SpectraWAVE Appoints Dr. Jonathan Hill, MD as Chief Medical Officer

Audio By Carbonatix

BEDFORD, Mass.--(BUSINESS WIRE)--Sep 30, 2025--

SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), today announced the appointment of Dr. Jonathan Hill, MD, as Chief Medical Officer. Dr. Hill, a globally renowned interventional cardiologist from Royal Brompton Hospital in London, brings extensive expertise in coronary artery disease, complex PCI, intravascular imaging, physiology, cardiovascular innovation, and clinical study design and implementation.

“Jonathan is a highly respected clinician and innovator whose leadership will be critical as SpectraWAVE accelerates commercial adoption and advances its clinical evidence strategy both in the US and worldwide for our expanding product portfolio,” said Eman Namati, PhD, Chief Executive Officer of SpectraWAVE. “His experience integrating intravascular imaging and physiology into daily clinical practice, and being at the front lines of medicine with multiple major worldwide clinical studies will strengthen our partnerships with physicians, research groups, and support our commitment to improving outcomes for CAD patients.”

The announcement comes as SpectraWAVE surpasses thousands of commercial HyperVue™ Imaging System cases in cath labs across the United States and achieves multiple clinical study milestones. The company recently completed enrollment of a 175-patient U.S. clinical workflow study of HyperVue, its state of the art DeepOCT™+NIRS intravascular imaging system, with results scheduled to be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 meeting October in San Francisco. In addition, SpectraWAVE has initiated a multi-site U.S. study evaluating its upcoming single-angiogram wire-free FFR technology, currently under review by the FDA.

“I am honored to join SpectraWAVE at such a pivotal time,” said Dr. Hill. “The company’s approach to combining intravascular imaging and physiology in a comprehensive and easy-to-use form factor is going to transform decision-making in the cath lab. I look forward to collaborating with the incredible team and the global clinical community as we expand the impact of HyperVue and introduce new technologies and clinical indications beyond intravascular imaging.”

SpectraWAVE will be at booth 2027 at TCT 2025 in San Francisco, providing demonstrations of the HyperVue Imaging System. In addition, SpectraWAVE will host an Academic Satellite Program Monday, October 27 th, 3:45-4:45 PM local time at the Moscone Convention Center.

About SpectraWAVE, Inc.

SpectraWAVE, located in Bedford, Mass., is a privately held medical device company founded in 2017 to provide unrivaled optical and computational insights to improve the treatment and outcomes for patients with coronary artery disease (CAD). CAD, the buildup of plaque in the wall of the arteries that supply blood to the heart, affects 20.5 million adults aged 20 and older. In CAD patients that undergo percutaneous stent placement, it is estimated that one in five patients experience adverse events within two years. SpectraWAVE’s flagship HyperVue™ Imaging System combines next generation DeepOCT™ images and near infrared spectroscopy (NIRS) with workflows optimized for the cardiac catheterization lab, and serves as a central hub for future enhancements that will continue to empower interventionalists in their treatment decision making and optimization. The HyperVue Imaging System is intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The NIRS capability of the system is intended for the identification of patients and plaques at increased risk of major adverse cardiac events. For more information and complete indications for use, please visit www.spectrawave.com.

HyperVue, Starlight, and DeepOCT are commercial trademarks cleared for sale in the U.S.A.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250930680673/en/

CONTACT: Media:

SpectraWAVE, Inc.

Jason Tucker-Schwartz, PhD

[email protected]

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH FDA MEDICAL DEVICES HEALTH TECHNOLOGY RADIOLOGY CLINICAL TRIALS CARDIOLOGY

SOURCE: SpectraWAVE, Inc.

Copyright Business Wire 2025.

PUB: 09/30/2025 08:05 AM/DISC: 09/30/2025 08:04 AM

http://www.businesswire.com/news/home/20250930680673/en